Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro

American Journal of Physiology - Endocrinology and Metabolism

Volumn 288, Issue 1 51-1, 2005, Pages

  Petersen, E W ^a   Carey, A L ^b   Sacchetti, M ^a   Steinberg, G R ^c   Macaulay, S L ^d   Febbraio, M A ^b   Pedersen, B K ^a,e  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b RMIT UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d CSIRO   (Australia)

^e University of Copenhagen   (Denmark)

Author keywords

Cytokines; Insulin sensitivity; Metabolism

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADRENALIN; CARBON 13; CARBON 14; DEXAMETHASONE; GLUCAGON; GLUCOSE; GROWTH HORMONE; HYDROCORTISONE; INSULIN; NORADRENALIN; PALMITIC ACID; RECOMBINANT INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADRENALIN BLOOD LEVEL; AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CATALYST; CELL STRAIN 3T3; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; ISOTOPE LABELING; LIPOLYSIS; MALE; MUSCLE CELL; MYOTUBE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL;

EID: 11144325623     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00257.2004     Document Type: Article

References (31)

1. Asada N, Takahashi Y, and Honjo M. Effects of 22K or 20K human growth hormone on lipolysis, leptin production in adipocytes in the presence and absence of human growth hormone binding protein. Harm Res 54: 203-207, 2000.
2. Balent B, Goswami G, Goodloe G, Rogatsky E, Rauta O, Nezami R, Mints L, Angeletti RH, and Stein DT. Acute elevation of NEFA causes hyperinsulinemia without effect on insulin secretion rate in healthy human subjects. Ann NY Acad Sci 967: 535-543, 2002.
3. Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, and Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87: 2084-2089, 2002.
4. Buschard K, Aaen K, Horn T, Van Damme J, and Bendtzen K. Interleukin 6: a functional and structural in vitro modulator of beta-cells from islets of Langerhans. Autoimmunity 5: 185-194, 1990.
5. Djurhuus CB, Gravholt CH, Nielsen S, Pedersen SB, Møller N, and Schmitz O. Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. Am J Physiol Endocrinol Metab 286: E488-E494, 2004.
6. Hjemdahl P, Daleskog M, and Kahan T. Determination of plasma catecholamines by high performance liquid chromatography with electrochemical detection: comparison with a radioenzymatic method. Life Sci 25: 131-138, 1979.
7. Horber FF, Marsh HM, and Haymond MW. Differential effects of prednisone and growth hormone on fuel metabolism and insulin antagonism in humans. Diabetes 40: 141-149, 1991.
8. Jensen MD. Cytokine regulation of lipolysis in humans? J Clin Endocrinol Metab 88: 3003-3004, 2003.
9. Kelley DE and Mandarine LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 49: 677-683, 2000.
10. Klover PJ, Zimmers TA, Koniaris LG, and Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52: 2784-2789, 2003.
11. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, and Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 311: 372-379, 2003.
12. Lam TK, Carpentier A, Lewis GF, van de Werve G, Fantus IG, and Giacca A. Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol Metab 284: E863-E873, 2003.
13. Lyngso D, Simonsen L, and Bulow J. Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol 543: 379-386, 2002.
14. Makino T, Noguchi Y, Yoshikawa T, Doi C, and Nomura K. Circulating interleukin 6 concentrations and insulin resistance in patients with cancer. Br J Surg 85: 1658-1662, 1998.
15. Rebuffe-Scrive M, Walsh UA, McEwen B, and Rodin J. Effect of chronic stress and exogenous glucocorticoids on regional fat distribution and metabolism. Physiol Behav 52: 583-590, 1992.
16. Rizza RA, Mandarino LJ, and Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab 54: 131-138, 1982.
17. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, and Shulman GI. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97: 2859-2865, 1996.
18. Rotter V, Nagaev I, and Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278: 45777-45784, 2003.
19. Sandier S, Bendtzen K, Eizirik DL, and Welsh M. Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology 126: 1288-1294, 1990.
20. Senn JJ, Klover PJ, Nowak IA, and Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51: 3391-3399, 2002.
21. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, and Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 17: 884-886, 2003.
22. Starkie RL, Rolland J, Angus DJ, Andersen MJ, and Febbraio MA. Circulating monocytes are not the source of elevations in plasma IL-6 and TNF-a levels after prolonged running. Am J Physiol Cell Physiol 280: C769-C774, 2001.
23. Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van Hall G, Febbraio MA, and Pedersen BK. Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol 548: 631-638, 2003.
24. Steinberg GR and Dyck DJ. Development of leptin resistance in rat soleus muscle in response to high-fat diets. Am J Physiol Endocrinol Metab 279: E1374-E1382, 2000.
25. Stouthard JM, Oude Elferink RP, and Sauerwein HP. Interleukin-6 enhances glucose transport in 3T3-L1 adipocytes. Biochem Biophys Res Commun 220: 241-245, 1996.
26. Stouthard JM, Romijn JA, van der Poll T, Endert E, Klein S, Bakker PJ, Veenhof CH, and Sauerwein HP. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol Endocrinol Metab 268: E813-E819, 1995.
27. Van Hall G, Sacchetti M, Radegran G, and Saltin B. Human skeletal muscle fatty acid and glycerol metabolism during rest, exercise and recovery. J Physiol 543: 1047-1058, 2002.
28. Van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA, and Pedersen BK. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88: 3005-3010, 2003.
29. Wallenius K, Jansson JO, and Wallenius V. The therapeutic potential of interleukin-6 in treating obesity. Exp Opin Biol Ther 3: 1061-1070, 2003.
30. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, and Jansson JO. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8: 75-79, 2002.
31. iα2 to lower density membrane fractions. Endocrinology 140: 1219-1227, 1999.